Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AxSpA Clear all
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 10, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional Results available

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03232580
View directory record Official record
Conditions
Spondyloarthritis
Interventions
rhAnnexin V-128
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 10, 2026, 9:56 PM EDT
Active, not recruiting Not applicable Interventional

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT05715463
View directory record Official record
Conditions
Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions
Resource sheets, Community Resource Specialist, Nurse Navigator
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 10, 2026, 9:56 PM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 10, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

NCT00811499
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 10, 2026, 9:56 PM EDT
Not yet recruiting Phase 4 Interventional

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

NCT07018206
View directory record Official record
Conditions
Axial Spondylarthritis (axSpA)
Interventions
Upadacitinib 15 MG [Rinvoq]
Drug
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

NCT01786668
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 10, 2026, 9:56 PM EDT
Recruiting No phase listed Observational

IMPACT - AndHealth Autoimmune Research Registry

NCT05883371
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions
Root-cause autoimmune treatment program
Other
Lead sponsor
AndHealth
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 10, 2026, 9:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Ankylosing Spondylitis

NCT00081562
View directory record Official record
Conditions
Spondylitis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Sep 10, 2026, 9:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Development of Spondyloarthritis

NCT01422694
View directory record Official record
Conditions
Arthritis, Spondylitis, Ankylosing
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

NCT02696785
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Early Phase 1 Interventional

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

NCT00643526
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions
Pre-filled Auto-injector Containing Placebo
Device
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 10, 2026, 9:56 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036
View directory record Official record
Conditions
Psoriatic Arthritis, Axial Spondyloarthritis
Interventions
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Peoria, Arizona • Apple Valley, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

NCT02008916
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 10, 2026, 9:56 PM EDT
Active, not recruiting No phase listed Observational

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT02281747
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
20 Years to 100 Years
Enrollment
521,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 9:56 PM EDT
Terminated Not applicable Interventional

Clinical Investigation of MONTAGE in Adults With Spinal Deformity Undergoing Pedicle Subtraction Osteotomy

NCT04125147
View directory record Official record
Conditions
Fused Vertebrae, Ankylosing Spondylitis, Sagittal Deformities, Thoracolumbar Kyphosis
Interventions
Experimental: Montage Bone Hemostat
Device
Lead sponsor
Abyrx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

NCT01109940
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457A
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 4 Interventional Results available

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA

NCT02509026
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Etanercept
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Pensacola, Florida • Chicago, Illinois • Mineola, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 10, 2026, 9:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT02963506
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Anniston, Alabama • La Jolla, California • Upland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 10, 2026, 9:56 PM EDT